Appendix 4E and 2017 Annual Report
Filed with ASX · · 56 pages · English
$ Dividends There were no dividends paid, recommended or declared during the current financial period. Comments During the period, the Group had total revenue of $531,729 (2016: $867,653), consisting of the R&D tax incentive of $410,163 (2016: $502,485), licencing income of $52,708 (2016: $247,970), interest income of $44,512 (2016: $76,869) and government grants revenue of $23,791 (2016: $Nil). T
Story so far
Earlier from Patrys
- Appendix 4C - Quarterly - 30 June 2017
- Patrys Deoxymab 3E10 patent granted in the U.S.
- PAB Licences Deoxymab 3E10 - nanoparticle IP from Yale
- Finance Update
- Appendix 4C - Quarterly - 31 March 2017
Later from Patrys
- PAT-DX1 Active in Pre-clinical Cancer Models
- PAT-DX1 Conjugated to Nanoparticles, Targets Tumors
- US Patent Granted for Preclinical Candidate PAT-LM1
- PAB and Garvan Institute of Medical Research Awarded Grant
- Appendix 4C - Quarterly - 30 September 2017
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys